BACKGROUND: Drug-induced QT interval prolongation, a risk factor for life-threatening ventricular arrhythmias, is a potential side effect of many marketed and withdrawn medications. The contribution of common genetic variants previously associated with baseline QT interval to drug-induced QT prolongation and arrhythmias is not known.
T he US government recently launched a Precision
Medicine Initiative to move away from a "one size fits all approach" for medical therapies and instead take into account specific characteristics of individual patients. 1 Outside of oncology, advances in pharmacogenomics have been limited, with the exception of the genetic basis of drug absorption, distribution, metabolism, and excretion (pharmacokinetics), which are traits often controlled by 1 or a few genetic mechanisms rather than the many mechanisms responsible for most complex traits and diseases. Drug-induced QT prolongation (reflecting delayed ventricular repolarization), which is a risk factor for torsade de pointes, is a potential side effect of many marketed and withdrawn medications through their direct actions on the heart (pharmacodynamics). 2 We previously performed genome-wide association studies (GWASs) of the electrocardiographic QT interval identifying many common genetic variants that contribute a modest increment to resting QT interval (eg, ≈1 to 3 milliseconds per allele) when considered individually. [3] [4] [5] We demonstrated that a genetic QT score is a strong predictor of baseline QT interval, with individuals in the top quintile having a 15-millisecond-higher QT interval compared with individuals in the bottom quintile, 6 explaining up to 10% of QT variation (≈25% of its heritability). 4 In the present study, we test the hypothesis that a weighted combination of common genetic variants contributing to QT at baseline will predict individual response to multiple QT-prolonging drugs and risk of torsade de pointes in a case-control study.
METHODS

Clinical Study Design
The study was approved by the US Food and Drug Administration Research Involving Human Subjects Committee and local institutional review boards. All subjects gave written informed consent. The study design and primary results (not including genetic analysis) have been previously published. 7, 8 The study was a randomized, double-blind, crossover study of healthy subjects ( Figure 1 ) at a phase 1 clinical research unit (Spaulding Clinical, West Bend, WI) to differentiate the effects of individual versus multichannel block on the ECG. The inclusion and exclusion criteria were similar to those for thorough QT studies. Subjects were 18 to 35 years old, 50 to 85 kg, and without a family history of cardiovascular disease or unexplained sudden cardiac death. Subjects also had to have a baseline heart rate-corrected QT (QTc) of <450 milliseconds for men (470 milliseconds for women) with the Fridericia correction and <12 ventricular ectopic beats during a 3-hour continuous recording at screening.
There was a 7-day washout period between each 24-hour treatment period. In the morning of each period, subjects received a single dose of 500 µg dofetilide (Tikosyn, Pfizer, New York, NY), 400 mg quinidine sulfate (Watson Pharma, Corona, CA), 1500 mg ranolazine (Ranexa, Gilead, Foster City, CA), 120 mg verapamil hydrochloride (Heritage Pharmaceuticals, Edison, NJ), or placebo. As previously reported, 7 verapamil did not prolong QTc at the dose administered and is not included in this analysis of the association of genetic variants with QTc prolongation.
Continuous ECGs were recorded at 500 Hz with an amplitude resolution of 2.5 µV. From the continuous recording, triplicate 10-second ECGs were extracted before dose and at 15 predefined time points over 24 hours after dose, during which the subjects were resting in a supine position for 10 minutes. ECGs were extracted with stable heart rates and maximum signal quality with Antares software (AMPS-LLC, New York, NY) at each of the 16 time points. 9 All postdose time points were time matched with blood samples for pharmacokinetic analysis. Plasma drug concentration was measured with a validated liquid chromatography with tandem mass spectroscopy method by Frontage Laboratories (Exton, Philadelphia, PA). 7 Semiautomatic adjudication of the ECG intervals of the upsampled ECGs was carried out by investigators blinded to treatment and time as previously described. 7 For identification of the peak of the T wave (T peak ) and end of the T wave (T end ), 2 ECG readers identified the global peak and end of the T wave in the vector magnitude lead derived from the Guldenring transformation matrix. 10 T peak was located by fitting a parabola through the T-wave peak. In the presence of a notch, the T peak was defined as the first discernible peak. T end was determined with the tangent method, which involves locating the intersection between the line through the terminal descending part of the T wave and isoelectric line. This approach of using the global vector magnitude lead to identify T peak and the tangent method for T end is not the same as T peak -T end measured in a precordial lead but produces more consistent measurements. In cases of low-amplitude, flat T waves, this results in longer QT intervals. Disagreements on a T wave being measureable, the presence of a notch, or a difference of >5 milliseconds in either T peak or T end were rereviewed and adjudicated by an expert ECG reader. This was the case for only ≈1.4% of ECGs. 7 QT was corrected for heart rate with the Fridericia formula (QTc), and J-T peak was corrected with the Johannesen formula (J-T peak c=J-T peak /RR 0.58 , with RR in seconds), whereas T peak -T end was not
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What Is New?
• We demonstrated that a genetic risk score comprising multiple independent genetic variants that have previously been found to be associated with QT interval duration is collectively associated with the degree of drug-induced QT prolongation.
• In addition, the genetic risk score was associated with drug-induced torsade de pointes in a case-control cohort.
What Are the Clinical Implications?
• If our results are confirmed in real-world collections of drug-exposed patients with larger sample sizes, the genetic risk score (updated as new variants are discovered) could potentially be used to individualize assessment of risks and benefits of drugs with high risk for drug-induced arrhythmias.
corrected for heart rate because it has minimal heart rate relationship at rest as previously described. 11 The annotated ECG median beats are available on Physionet at https://physionet. org/physiobank/database/ecgrdvq/. 12 A fully automated algorithm for T peak and T end is also now available at https://github. com/FDA/ecglib. 13 
DNA Extraction
Blood samples for isolation of DNA and genetic testing were collected and spotted onto Whatman FTA blood spot cards (Whatman Inc, Clifton, NJ) by a research team member at check-in of the first period. DNA was extracted from Whatman FTA blood spot cards with Promega Tissue and Hair Extraction (Promega, Inc, Madison, WI) kits. For samples with comparatively low yield, whole genome amplification was performed with the Qiagen REPLI-g Midi Kit (Qiagen, Inc, Venlo, Limburg, the Netherlands). Samples were plated in duplicate from both raw extracted DNA and amplified DNA.
Primer Selection and Design
Sixty-eight single-nucleotide polymorphisms (SNPs) with established independent effects on QT interval from a large GWAS in 76 061 individuals of European descent, all meeting the P<5×10 −8 threshold for statistical significance, 4 were targeted for design in 3 multiplex assays with Sequenom custom software. When assays for specific SNPs could not be designed, alternative SNPs that were highly correlated (r 2 >0.90 to the index SNP) and known to be equally associated with QT interval were attempted. In total, 63 SNPs were designed into 3 multiplexed pools; 5 SNPs could not be designed because of multiplexing limitations.
Genotyping and Quality Control
Sixty-three SNPs were attempted on the Sequenom matrixassisted laser desorption/ionization time-of-flight platform. DNA with and without whole-genome amplification was tested in duplicate (88 wells for 22 individuals) on 384-well plates, with DNA from an additional 200 individuals genotyped for a separate study. For a given individual in whom 2 samples were genotyped, the sample with the highest genotyping call rate was selected for analysis. Sixty-one SNPs with a call rate >90% and Hardy-Weinberg equilibrium P>0.001 across all plated samples (22+200) were retained for further analysis; 2 SNPs failed. The average genotyping success rate across 61 SNPs among 22 study subjects was 95.0%.
Genetic QT Score
A genotype score was calculated as previously described. 6 Briefly, the effects of 61 common variants on QT interval in individuals of European and of African descent were previously estimated in the Arking et al 4 GWAS. We use European or African descent when describing analyses that included genetic inference of continental ancestry and black or white when describing study subject self description. We oriented the coded allele (the allele coded 0, 1, or 2) to be the QT-raising allele for each SNP, regardless of allele frequency. A "simple" score just adding up the QT-increasing alleles across the 61 variants would have a theoretical minimum of 0 QT-prolonging alleles to a maximum of 122 QT-prolonging alleles because everyone has 2 alleles. This approach ignores the fact that not all genetic variants have equal effects on QT interval. Our approach (taken by most others in the genetics community) is to weight each allele by the observed effect on QT from the original 2014 GWAS. This changes the scale of the score from the number of QT-prolonging alleles to the predicted QT increase on the millisecond scale; predicted, not observed, because the weights are taken from the original GWAS, not the present study. The contribution of a given SNP to the QT score was weighted according to the effect estimate per coded allele. For example, rs12143842 is a C/T SNP of which the T allele has a frequency of 0.24 in individuals of European ancestry and is associated with a 3.5-millisecond-longer QT interval per allele copy. An individual homozygous for the major allele (CC) would have 0 copies of the QT-raising allele, and the contribution in that individual for that SNP to the QT score would be 0 (=3.5×0) milliseconds. An individual homozygous for the minor allele (TT) would have 2 copies of the QT-raising allele, and the contribution for that SNP to the QT score would be +7.0 (=3.5×2) milliseconds. This process is then repeated for all 61 SNPs, and the individual SNP contributions are summed. For SNPs with missing genotypes in a given individual, the contribution to the score was imputed from the allele frequency in the general population (twice the allele frequency because every individual has 2 copies of each gene). For example, for Twenty-four of the 52 screened subjects did not meet the inclusion criteria. Twenty-two of the 28 subjects who met the inclusion criteria were randomized. All subjects completed the study except 1 subject who withdrew before the last treatment period.
rs12143842, the coded allele frequency is 0.24, and the average number of coded alleles in individuals in the general population would be 0.24×2=0.48, and thus the contribution of a missing genotype for this SNP would be 1.68 (=3.5×0.48) milliseconds. The effect of such imputation biases the genotype score toward the null. In self-described white individuals in the present study, we used the allelic effects estimated from the prior GWAS in individuals of European ancestry (Table I in the online-only Data Supplement). As reported in the Arking et al 4 study, an independent African descent had a smaller sample size, and therefore, fewer SNPs reached stringent statistical significance (P<5×10 −8 ), accounting for the genome-wide multiple testing burden. However, we observed high correlation among the effects of SNPs identified in European-derived individuals with effects for the same SNPs estimated in a GWAS in 13 105 black individuals (r=0.60). 14 We cannot tell which SNPs among these are truly associated and which are not because of limitations of power; however, the estimates in African descent individuals for null SNPs (not truly associated) will tend to cancel each other out. Therefore, in self-described black individuals in the present study, we used the allelic effects estimated for 60 of the 61 SNPs (1 SNP was unavailable) in the earlier African descent GWAS. 14 The European-derived and African-derived genetic QT scores were calculated in all individuals, regardless of self-described ancestry, for comparison purposes, but ancestry-specific scores were tested as the primary analysis. The PLINK version 1.07 statistical package was used in all QT score calculations. Genotyping, quality control, and genetic QT score calculation were performed by coinvestigators blinded to all clinical data, including race, sex, and QTc response to drug.
Case-Control Analysis of Torsade de Pointes
A GWAS was previously performed on 216 individuals of European descent, with drug-induced torsade de pointes collected as part of the Trans-Atlantic Alliance Against Sudden Death supported by the Fondation Leducq and the DARE study (Drug-Induced Arrhythmia Risk Evaluation) compared with 771 ancestry-matched controls. 15 The control group included a sample of drug-exposed, ancestry-matched controls free of excessive QT prolongation and population-based controls. In the study of rare diseases such as rare adverse drug events, with incidence well below 1%, the frequencies of common variants among population-based controls and among drugexposed QT nonprolongers are expected to be broadly similar. In the original study of torsade cases, a diversity of potential offending drugs was observed, albeit enriched for users of quinidine, sotalol, and amiodarone. Considering the small number of cases, we used combined sets of drug-exposed and population-based controls to maximize the control size. Using the methods developed by Johnson and reported in Ehret et al, 16 we applied an instrumental variable approach based on the weighted effects from the QT Interval-International GWAS Consortium 4 on the risk of drug-induced torsade de pointes for 60 of the 68 total SNPs that were directly genotyped or imputed with imputation quality >0.90 in the torsade study. In a sensitivity analysis, we repeated the risk score analysis using only 1 SNP per locus (31 index SNPs from 35 possible loci). These analyses were performed in R (R Foundation for Statistical Computing, Vienna, Austria) with the "gtx" package (version 0.0.8) available at https://cran.r-project.org/web/ packages/gtx/index.html.
Statistical Analysis
Personalized ECG response to drug was defined as the slope of an individual subject's drug-induced change in ECG biomarker (Figure 2A-2C ). This was calculated by inputting individual-subject baseline (triplicate ECG measurements obtained immediately before dosing of a specific drug) and placebocorrected (time of day-matched ECG measurement from the placebo day) change (∆∆QTc) for each of the ECG biomarkers and plasma drug concentrations into PROC MIXED in SAS 9.3 (SAS Institute Inc, Cary, NC), with concentration as a fixed effect and subject as a random effect on concentration (ie, with each subject having his or her own slope with an intercept set to 0). The association between biomarkers (eg, ∆∆QTc/drug concentration slope versus genetic QT score) was tested with the Pearson product-moment correlation coefficient in R 3.1.2. The crossover design was not formally accounted for in the statistical analysis, except for calculating placebo-corrected change from baseline for all ECG biomarker measurements. Values of P<0.05 were considered statistically significant.
RESULTS
The drug study included 17 self-described white subjects, 4 black subjects, and 1 Asian subject free of electrolyte abnormality, concomitant medication use, or clinically apparent cardiovascular disease ( Table 1 ). The white group included 8 men and 9 women with a mean age of 26 years. The European genetic score explained 27% of the variability in baseline QTc in white subjects (P=0.03; Figure 2F ). The black genetic score was also correlated with baseline QTc in African subjects (P=0.03), although the small sample size limits precise estimation of the effect (Table II in the online-only Data Supplement).
Baseline QTc was not a significant predictor of druginduced QTc prolongation for any of the drugs in 17 white subjects, potentially as a result of limited power (Figure 2G and Figure I in the online-only Data Supplement). However, there was a significant correlation between the genetic QT score and drug-induced QTc prolongation (Table 2 and Figure I in the online-only Data Supplement). Among white subjects, European genetic score explained 30% of the variability (P=0.02) in response to dofetilide ( Figure 2H ), 23% in response to quinidine (P=0.06), and 27% in response to ranolazine (P=0.03). Among 4 black subjects, a significant correlation existed between baseline QTc and response to dofetilide (P=0.04; Table II in the online-only Data Supplement) and between the African genetic score and response to dofetilide (P=0.03, Table 2 ) but not for quinidine or ranolazine.
We next investigated how response to 1 QT-prolonging drug predicted the response to other QT-prolonging drugs, combining subjects of all races together. There were significant correlations between all drug-drug rela-tionships, with response to each drug explaining 24% to 29% of the variability in response to each of the other drugs ( Figure 2I and Table 3 ).
Although hERG potassium channel block prolongs both J-T peak c and T peak -T end intervals, additional inward current block from L-type calcium or late sodium current block can shorten the J-T peak c interval. 8, 17 Thus, T peak -T end may be a more specific marker for hERG potassium channel block than the entire QT interval. 7, 11 Genetic QT score was not associated with baseline T peak -T end or drug-induced change in T peak -T end (Table III in the online-only Data Supplement). Response to each of the 2 strongest hERG potassium channel-blocking drugs (dofetilide and quinidine) explained 52% of the variability in the response to the other (P<0.001; Table 3 ). Baseline T peak -T end was also correlated with drug-induced QTc prolongation for dofetilide and quinidine but not ranolazine (Table IV in the online-only Data Supplement), and baseline T peak -T end was correlated with drug-induced T peak -T end prolongation for all 3 drugs (Table V in the onlineonly Data Supplement).
To test the relevance of the impact of the genetic risk score on quantitative drug-induced QT response to the outcome for which QT response is a surrogate, we examined a previously published GWAS of drug-induced torsade de pointes. 15 From a GWAS in 216 individuals with drug-induced torsade de pointes of European descent compared with 771 ancestry-matched controls, 60 of 68 possible QT SNPs had adequate imputation quality or were directly genotyped and available for analysis (Table VI in ), explaining 12.1% of variation in risk (Figure 3) .
In a sensitivity analysis restricted to 1 SNP per locus, for which 31 SNPs at 35 loci were available, the genetic risk score explained a smaller proportion of variance in Figure 2 . Pharmacokinetic/pharmacodynamic (PK/PD) response and genetic QT score.
A, Pharmacokinetic time profile shows plasma dofetilide concentration at each of the 15 time points after dose (dots) for each subject (lines). Example subjects are shown in red (dofetilide high responder) and green (low responder) throughout. B, Pharmacodynamic time profile shows baseline-and placebo-corrected changes from baseline in heart rate-corrected QT (ΔΔQTc) at 15 time points (dots) after a single oral dose of dofetilide for each subject (lines). C, PK/PD response plot showing the measures of ΔΔQTc from the ECGs and the corresponding time-matched dofetilide plasma concentration. Solid lines show each subject's QTc concentration-dependent response, the slope of which was tested in genetic QT score analyses. ECG examples show lead II and QT/QTc measures of (D) a high responder subject (red line and dots in A-C) during placebo (top ECG) and dofetilide (bottom ECG) and (E) a low responder subject (green line and dots in A-C) during placebo (top ECG) and dofetilide (bottom ECG). Note that although lead II is shown, QT measurements are from the global vector magnitude lead as described in Methods. Correlations between (F) genetic QT score and baseline QTc in white subjects, (G) baseline QTc and dofetilide QTc response in white subjects, (H) genetic QT score and dofetilide QTc response in white subjects, and (I) dofetilide QTc response and quinidine QTc response in all subjects are shown. Each dot represents a subject's value. The scale of the QT genetic score is in milliseconds of predicted QT effect for the variants in aggregate, as described in Methods.
drug-induced QT prolongation, and significance was attenuated (Table VII in 
DISCUSSION
Drug-induced QT prolongation and torsade de pointes have resulted in the withdrawal of several drugs from the market, and >150 are listed on CredibleMeds.org as being associated with QT prolongation and/or torsade de pointes. 18 However, the incidence of torsade de pointes is low, and only a small number of patients develop drug-induced long-QT syndrome. The present pilot study provides a link between common genetic variants and drug-induced QT prolongation and demonstrates how GWAS results can be leveraged to define personalized pharmacodynamic response to drugs. Moreover, our finding that these same common genetic variants influence risk of drug-induced torsade de pointes confirms the potential clinical relevance of the genetic QT score.
A genetic component of long-QT syndrome has been recognized since the 1950s, 19 with the molecular basis of rare genetic variants causing congenital long-QT syndrome first identified in the 1990s. However, not all individuals with congenital long-QT syndrome variants have prolonged QT intervals at baseline, a hallmark of incomplete penetrance or expression of the genetic abnormality. Recent GWASs have identified >60 common genetic variants that individually have small effects on QT at baseline (eg, 1 to 3 milliseconds) but in aggregate may have a larger effect. Individual SNPs at the NO-S1AP locus and at KCNE1 have been associated with increased risk of acquired long-QT syndrome. 20, 21 Indeed, in the present study, we demonstrated that a weighted combination of 61 common genetic variants explained 27% of the variability in baseline QTc. This common genetic variability may help explain not only the incomplete penetrance of congenital long-QT syndrome [22] [23] [24] but also why only certain individuals without recognized congenital long-QT syndrome develop drug-induced long-QT syndrome and torsade de pointes.
Previous reports have suggested that patients developing drug-induced long-QT syndrome with 1 drug are more likely to develop drug-induced long QT syndrome with exposure to other drugs. 25 In addition, Kannankeril et al 26 studied the effects of quinidine on drug-induced QTc and T peak -T end prolongation in first-degree relatives of patients who developed drug-induced long-QT syndrome, including torsade de pointes, compared with relatives of patients who tolerated QT-prolonging therapy. Having a relative with drug-induced long-QT syndrome was associated with exaggerated T peak -T end prolongation, but not QTc prolongation, compared with having a drug-tolerant Age, body mass index (BMI), heart rate-corrected QT (QTc), and genetic QT score values are reported as mean±SD. Table 2 relative, although the sample size was limited. 26 This is consistent with our recent findings that global T peak -T end measured in the vector magnitude lead may be a more specific biomarker than QT prolongation for hERG potassium channel block, 7, 8, 11 and in the present study, response to the 2 strongest hERG blockers (dofetilide and Instrumental variable analysis of effect of 60 single-nucleotide polymorphisms (SNPs) associated with resting QTc using effect estimates from the QT Interval-International GWAS Consortium (QT-IGC) genome-wide association study (x axis) in milliseconds of predicted QT interval per allele as a predictor of log odds ratio of drug-induced TdP (y axis). Individual labels represent SNPs used in the analysis, and error bars correspond to the standard error of the log odds ratio [ln(OR)] of drug-induced TdP. For example, the QT-raising allele of SNP rs12143842 is associated with a 3.5-millisecond-longer QT interval ( quinidine) explained 52% of the variability in response to the other. However, the genetic QT score was not associated with baseline or drug-induced T peak -T end prolongation. This is not surprising because the common genetic variants were selected for association with the whole QT interval, not just the T peak -T end component. Nonetheless, the relationship between T peak -T end measurements at baseline and individual-subject drug response suggests that further study should investigate the relationship between T peak -T end , common genetic variants and risk. Repolarization reserve, as originally proposed, 27, 28 suggests that multiple redundant mechanisms contribute to repolarization such that minor alterations (eg, from genetic variants) may not be detectable at baseline. However, in the presence of additional insults such as hypokalemia or exposure to a drug, reduced repolarization reserve can be unmasked, resulting in an extreme drug response that can lead to ventricular arrhythmias. 29 This model has been considered largely in the context of mendelian long-QT syndromes, in which some ion channel mutation carriers only manifest life-threatening arrhythmia after drug exposure. Although cases of subclinical Mendelian long-QT syndrome exposed by the development of torsade de pointes on drug challenge are well recognized, they appear to represent a minority of cases of drug-induced long-QT syndrome. [30] [31] [32] Our genetic and drug A versus drug B response findings strongly support that a significant proportion of repolarization reserve 27, 28 in apparently healthy subjects has a genetic basis and that a relatively modest number of common variants-many in genes without an established role in mendelian long-QT syndromes-in aggregate play a substantial role. That the genetic QT score is associated with increased risk of drug-induced torsade de pointes supports the clinical relevance of these variants and confirms the established relationship between QT prolongation after drug exposure and torsade de pointes risk. However, precise quantification of risk of torsade de pointes will be challenging because of the rarity of the outcome and the modest sample size of existing casecontrol collections.
The present study is limited by the small sample size, especially for blacks, and attempted replication is needed to confirm the findings in individuals of European descent, to provide more precise estimates of effects, and to perform adequately powered tests in individuals of African and other non-European ancestries. The study was conducted in healthy volunteers as opposed to patients, in whom sources of variation in QT response may be greater. However, the study represents a proof of principle that common genetic variants in aggregate influence QT response by administering multiple QT-prolonging drugs to the same subjects in a phase 1 clinical trial unit with pharmacokinetic/pharmacodynamic modeling to precisely define personalized response. We have imputed results for missing genotypes, although this is expected to bias results to the null. In addition, aggregating individual effects of variants in genes in diverse pathways does not establish which variants drive the risk of QT prolongation and torsade. We took a genetic risk score approach to maximize power under a model in which QT-prolonging alleles generally increase QT prolongation after drug exposure. Ultimately, much larger sample sizes, including, for example, individuals with the underlying cardiovascular diseases for which antiarrhythmic medications such as those examined here are prescribed, will be required to establish which variants contribute to the predictive ability of the score and the relative explanatory power of a genetic risk score when set against other clinical predictors of QT interval response.
Individualized prediction of risk of adverse response to medication is needed. Our finding that a simple genetic risk score comprising 61 common variants explains a substantial proportion of variation in QT response to multiple drugs highlights the opportunity to translate GWAS findings to clinical care. Genetic risk scores will be expanded as more genetic variants are identified. The present study highlights the value of genetic studies of continuous, quantitative cardiovascular traits measured in very large sample sizes to identify variants that have meaningful effects on clinical outcomes captured in much smaller samples. Studies to examine whether preemptive, preprescription genotyping leads to a reduction in serious adverse events are warranted.
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